- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.
Being based in Europe can have unique challenges for a company like Polpharma Biologics, a contract development and manufacturing organization (CDMO) with facilities in Poland and the Netherlands that specializes in biologics. Despite facing hurdles such as navigating partnerships to commercialize in multiple markets, developing complex molecules for international partners, and figuring out how to handle coronavirus disease 2019 (COVID-19) with facilities in 2 countries, Polpharma Biologics has grown to become a powerhouse, having 7 biosimilars in its pipeline and partnerships with Sandoz and Bioeq.
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other CDMOs function and how companies choose which molecules to develop.
To check out more of our coverage of Polpharma Biologics, click here.
To learn more about Polpharma's natalizumab clinical trial, click here.
To learn about Polpharma Biologics recent integration efforts, click here.
To learn more about Polpharma Biologics, click here.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
